Diamyd's Type 1 Diabetes Drug Advancing
Posted on: Friday, 25 August 2006, 15:01 CDT
Swedish firm Diamyd said Friday the diabetes drug it is testing showed promise in a phase 2 study in patients with type 1 diabetes.
The company said its investigational drug Diamyd showed efficacy in preserving insulin production in a clinical trial enrolling 70 children and adolescents with type 1 diabetes. The firm noted the study showed no serious adverse events linked to the treatment.
In the phase 2 trial, 35 patients recently diagnosed with type 1 diabetes receiving the test drug produced approximately twice as much meal-stimulated insulin -- as measured by C-peptide -- 15 months after the first treatment, compared to those on placebo.
This is a breakthrough, said Johnny Ludvigsson, professor of pediatrics at the University Hospital at Linkoping University in Stockholm, Sweden, and lead researcher in the eight-hospital study.
This clearly offers the potential to improve treatment of type 1 diabetes. Endogenous insulin production is very important as it helps patients to better control their disease and reduce complications.
Diamyd was given to patients in two injections, he said.
Source: United Press International
Related Articles
- Many Heart Failure Patients Do Not Get Proper Drug Treatments
- AACE Releases New Diabetes Algorithm for Treatment of Patients with Type 2 Diabetes
- Oculus Completes Patient Treatment in Phase II Diabetic Foot Ulcer Trial
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Seventy-Eight Percent of Newly Diagnosed Dyslipidemia Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- Experts Available To Discuss Study Showing New Drug is an Effective Treatment for Rheumatoid Arthritis
- Study: Drug Underprescribed Cholesterol-Lowering Statins Not Getting to at-Risk Heart Disease Patients
- Study Shows Cholesterol Drugs Underprescribed
 |
 |
User Comments (0)
RSS Feeds